Core Points - DXS International plc's Chairman, Mr. Bob Sutcliffe, purchased 50,000 Ordinary Shares at a price of 1.30p per share on 11 November 2025 [1][3] - Following this transaction, Mr. Sutcliffe and his wife hold a total of 1,383,756 Ordinary Shares, representing 2.16% of the company's issued share capital [2] Transaction Details - The transaction involved the purchase of Ordinary Shares with a nominal value of 0.33p each [3] - The transaction took place on the Aquis Stock Exchange [3] Company Overview - DXS International provides clinical decision support systems that deliver up-to-date treatment guidelines and recommendations from trusted NHS sources to healthcare professionals [4] - The company's solutions aim to improve healthcare outcomes while contributing to the NHS's efficiency savings [4]

Core Viewpoint - DXS International plc has granted share options and warrants to directors, employees, and consultants to align their interests with shareholders and incentivize performance [2][3][5]. Share Options - A total of 6,150,000 share options have been granted under the Enterprise Management Incentive (EMI) scheme, with an exercise price of 8p per share [3]. - Of the EMI options, 3,900,000 replace expired Directors' Share Options with no performance conditions or vesting periods [3]. - An additional 2,250,000 EMI options have a 2-year vesting period, with one third vesting on grant, one third on the anniversary, and the final third on the second anniversary [3][4]. Non-Tax Advantaged Options - 1,220,000 options have been granted under a non-tax advantaged option scheme, also with a 2-year vesting period structured similarly to the EMI options [4]. Warrants - The Board has replaced 1,341,402 expired warrants with new warrants at an exercise price of 4p per share, matching existing advisor warrants [5]. - Additionally, 150,000 new advisor warrants have been issued at an exercise price of 8p per share, with all new warrants having a 5-year exercise period from the grant date [5]. Company Overview - DXS International provides clinical decision support systems that deliver up-to-date treatment guidelines to healthcare professionals, aiming to improve healthcare outcomes and contribute to NHS efficiency savings [7].